INVIVYD completes enrollment in Phase 3 COVID antibody trial

June 16, 2026 7:01 AM

Invivyd, Inc. (NASDAQ: IVVD) announced that enrollment in its Phase 3 LIBERTY clinical trial is complete, with topline data expected ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found